Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1205-1211

  Sugano, Masayuki ^a   Shimizu, Kimihiro ^a   Nakano, Tetsuhiro ^a   Kakegawa, Seiichi ^a   Miyamae, Yohei ^a   Kaira, Kyoichi ^a   Araki, Takuya ^b   Kamiyoshihara, Mitsuhiro ^a   Kawashima, Osamu ^a   Takeyoshi, Izumi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Computed tomography; Epidermal growth factor receptor; KRAS; Pulmonary adenocarcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PRIORITY JOURNAL; RECEPTOR GENE; SEX DIFFERENCE; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80053144361     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1412     Document Type: Article

References (39)

1. Tam IY, Chung LP, Suen WS, et al: Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12: 1647-1653, 2006.
2. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
3. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
4. Mounawar M, Mukeria A, Le Calvez F, et al: Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 67: 5667-5672, 2007.
5. Suzuki M, Shigematsu H, Iizasa T, et al: Exclusive mutation in epidermal growth factor receptor gene, HERer-2, and KRAS, and synchronous methylation of non-small cell lung cancer. Cancer 106: 2200-2207, 2006.
6. Pao W and Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556-2568, 2005.
7. Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865, 2005.
8. Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282, 2005.
9. Asano H, Toyooka S, Tokumo M, et al: Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin 12: 43-48, 2006.
10. Nomoto K, Tsuta K, Takano T, et al: Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 126: 608-615, 2006.
11. Horiike A, Kimura H, Nishio K, et al: Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 131: 1628-1634, 2007.
12. Hashizume T, Yamada K, Okamoto N, et al: Prognostic significance of thin-section CT scan findings in small-sized lung adenocarcinoma. Chest 133: 441-447, 2008.
13. Yoshida Y, Kokubu A, Suzuki K, et al: Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity. Jpn J Clin Oncol 37: 907-912, 2007.
14. Yano M, Sasaki H, Kobayashi et al: Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol 1: 413-416, 2006.
15. Aoki T, Nakata H, Watanabe H, et al: Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. AJR Am J Roentgenol 174: 763-768, 2000.
16. Hoshi K, Takakura H, Mitani Y, et al: Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res 13: 4974-4983, 2007.
17. Mitani Y, Lezhava A, Kawai et al: Rapid SNP diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology. Nnat Methods 4: 257-262, 2007.
18. Tatsumi K, Mitani Y, Watanabe J, et al: Rapid screening assay for KRAS mutations by the modified smart amplification process. J Mol Diagn 10: 520-526, 2008.
19. Ciardiello F, De Vita F, Orditura M and Tortora G: The role of EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 16: 130-135, 2004.
20. slebos RJ, Kibbelaar RE, Dalesio O, et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. Nn Engl J Med 323: 561-565, 1990.
21. Buttitta F, Barassi F, Fresu G, et al: Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 119: 2586-2591, 2006.
22. Finberg KE, Sequist LlV, Joshi VA, et al: Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 9: 320-326, 2007.
23. Araki Shimizu K, Nnakamura K, et al: Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods. J Mol Diagn 12: 118-124, 2010.
24. Riely GJ, Kris MG, Rosenbaum D, et al: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: 5731-5734, 2008.
25. Marks JL, Broderick Zhou Q, et al: Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3: 111-116, 2008.
26. Suzuki K, Asamura H, Kusumoto M, Kondo H and Tsuchiya R: 'Early' peripheral lung cancer: prognostic significance of ground glass opacity on thin-section computed tomographic scan. Ann Surg 74: 1635-1639, 2002.
27. Asamura H, Suzuki K, Watanabe S, Matsuno Y, Maeshima A and Tsuchiya R: A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions. Ann 76: 1016-1022, 2003.
28. Glynn C, Zakowski MF and Ginsberg MS: Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? J Thorac Oncol 5: 344-348, 2010.
29. Haneda H, Sasaki H, Lindeman et al: A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn J Clin Oncol 36: 69-75, 2006.
30. Nose N, Sugio K, Oyama T, et al: Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 27: 411-417, 2009.
31. Harichand-Herdt S and Ramalingam SS: Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. Semin 36: 572-580, 2009.
32. Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L and Pietras RJ: Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 72: 135-143, 2007.
33. Aoki Tomoda Y, Watanabe H, et al: Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology 220: 803-809, 2001.
34. Nakanishi H, Matsumoto S, Iwakawa R, et al: Whole genome comparison of allelic imbalance between non-invasive and invasive small-sized lung adenocarcinomas. Cancer Res 69: 1615-1623, 2009.
35. Soh J, Toyooka S, Ichihara S, et al: Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol 3: 340-347, 2008.
36. Woo T, Okudela K, Yazawa et al: Prognostic value of KRAS mutations and Ki-67 expression in stage I lung denocarcinomas. Lung Cancer 65: 355-362, 2009.
37. Fong Morgensztern D and Govindan R: RGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 3: 303-310, 2008.
38. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. J Clin Oncol 22: 1103-1109, 2004.
39. Zakowski MF, Hussain Pao W, et al: Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med 133: 470-477, 2009.